Emma C Wall1,2,3, Philip Brownridge4, Gavin Laing5, Vanessa S Terra6, Veronica Mlozowa3, Brigitte Denis3, Mulinda Nyirenda7,8, Theresa Allain8, Elisa Ramos-Sevillano9, Enitan Carrol10, Andrea Collins5,11, Stephen B Gordon3,5, David G Lalloo5, Brendan Wren6, Robert Beynon4, Robert S Heyderman2,3, Jeremy S Brown9. 1. The Francis Crick Institute, London, United Kingdom. 2. Division of Infection and Immunity, University College London, London, United Kingdom. 3. Malawi-Liverpool-Wellcome Trust Clinical Research Programme, College of Medicine, University of Malawi, Blantyre, Malawi. 4. Centre for Proteomics, Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom. 5. Liverpool School of Tropical Medicine, Liverpool, United Kingdom. 6. London School of Hygiene and Tropical Medicine, London, United Kingdom. 7. Adult Emergency Trauma Centre, Queen Elizabeth Central Hospital, Ministry of Health, Blantyre, Malawi. 8. College of Medicine, University of Malawi, Blantyre, Malawi. 9. UCL Respiratory, Division of Medicine, University College London, London, United Kingdom. 10. Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom. 11. Liverpool University Hospital Foundation Trust, Liverpool, United Kingdom.
Abstract
Background: Mortality from bacterial meningitis, predominately caused by Streptococcus pneumoniae, exceeds 50% in sub-Saharan African countries with high HIV prevalence. Underlying causes of high mortality are poorly understood. We examined the host and pathogen proteome in the CSF of adults with proven pneumococcal meningitis (PM), testing if there was an association between differentially expressed proteins and outcome. Materials/ Methods: CSF proteomes were analyzed by quantitative Mass-Spectrometry. Spectra were identified using the Swissprot human and TIGR4 pneumococcal protein libraries. Proteins were quantitated and analyzed against mortality. Unique proteins in PM were identified against published normal CSF proteome. Random-Forest models were used to test for protein signatures discriminating outcome. Proteins of interest were tested for their effects on growth and neutrophil opsonophagocytic killing of S. pneumoniae. Results: CSF proteomes were available for 57 Adults with PM (median age 32 years, 60% male, 70% HIV-1 co-infected, mortality 63%). Three hundred sixty individual human and 23 pneumococcal proteins were identified. Of the human protein hits, 30% were not expressed in normal CSF, and these were strongly associated with inflammation and primarily related to neutrophil activity. No human protein signature predicted outcome. However, expression of the essential S. pneumoniae protein Elongation Factor Tu (EF-Tu) was significantly increased in CSF of non-survivors [False Discovery Rate (q) <0.001]. Expression of EF-Tu was negatively co-correlated against expression of Neutrophil defensin (r 0.4 p p < 0.002), but not against complement proteins C3 or Factor H. In vitro, addition of EF-Tu protein impaired S. pneumoniae neutrophil killing in CSF. Conclusions: Excessive S. pneumoniae EF-Tu protein in CSF was associated with reduced survival in meningitis in a high HIV prevalence population. We show EF-Tu may inhibit neutrophil mediated killing of S. pneumoniae in CSF. Further mechanistic work is required to better understand how S. pneumoniae avoids essential innate immune responses during PM through production of excess EF-Tu.
Background: Mortality from bacterial meningitis, predominately caused by Streptococcus pneumoniae, exceeds 50% in sub-Saharan African countries with high HIV prevalence. Underlying causes of high mortality are poorly understood. We examined the host and pathogen proteome in the CSF of adults with proven pneumococcal meningitis (PM), testing if there was an association between differentially expressed proteins and outcome. Materials/ Methods: CSF proteomes were analyzed by quantitative Mass-Spectrometry. Spectra were identified using the Swissprot human and TIGR4 pneumococcal protein libraries. Proteins were quantitated and analyzed against mortality. Unique proteins in PM were identified against published normal CSF proteome. Random-Forest models were used to test for protein signatures discriminating outcome. Proteins of interest were tested for their effects on growth and neutrophil opsonophagocytic killing of S. pneumoniae. Results: CSF proteomes were available for 57 Adults with PM (median age 32 years, 60% male, 70% HIV-1 co-infected, mortality 63%). Three hundred sixty individual human and 23 pneumococcal proteins were identified. Of the human protein hits, 30% were not expressed in normal CSF, and these were strongly associated with inflammation and primarily related to neutrophil activity. No human protein signature predicted outcome. However, expression of the essential S. pneumoniae protein Elongation Factor Tu (EF-Tu) was significantly increased in CSF of non-survivors [False Discovery Rate (q) <0.001]. Expression of EF-Tu was negatively co-correlated against expression of Neutrophil defensin (r 0.4 p p < 0.002), but not against complement proteins C3 or Factor H. In vitro, addition of EF-Tu protein impaired S. pneumoniae neutrophil killing in CSF. Conclusions: Excessive S. pneumoniaeEF-Tu protein in CSF was associated with reduced survival in meningitis in a high HIV prevalence population. We show EF-Tu may inhibit neutrophil mediated killing of S. pneumoniae in CSF. Further mechanistic work is required to better understand how S. pneumoniae avoids essential innate immune responses during PM through production of excess EF-Tu.
Authors: Tatiana Barichello; Joelson C Lemos; Jaqueline S Generoso; Andreza L Cipriano; Graziele L Milioli; Danielle M Marcelino; Francieli Vuolo; Fabricia Petronilho; Felipe Dal-Pizzol; Márcia Carvalho Vilela; Antonio Lucio Teixeira Journal: Neurochem Res Date: 2011-06-03 Impact factor: 3.996
Authors: Alfonso Olaya-Abril; Rafael Prados-Rosales; Michael J McConnell; Reyes Martín-Peña; José Antonio González-Reyes; Irene Jiménez-Munguía; Lidia Gómez-Gascón; Javier Fernández; José L Luque-García; Carlos García-Lidón; Héctor Estévez; Jerónimo Pachón; Ignacio Obando; Arturo Casadevall; Liise-Anne Pirofski; Manuel J Rodríguez-Ortega Journal: J Proteomics Date: 2014-04-24 Impact factor: 4.044
Authors: Emma C Wall; Stephen B Gordon; Samia Hussain; Upali R S Goonetilleke; Jenna Gritzfeld; Matthew Scarborough; Aras Kadioglu Journal: Clin Infect Dis Date: 2012-01-11 Impact factor: 9.079
Authors: Emma C Wall; Mavuto Mukaka; Matthew Scarborough; Katherine M A Ajdukiewicz; Katharine E Cartwright; Mulinda Nyirenda; Brigitte Denis; Theresa J Allain; Brian Faragher; David G Lalloo; Robert S Heyderman Journal: Clin Infect Dis Date: 2017-02-15 Impact factor: 9.079
Authors: Mark W Tenforde; Margaret Mokomane; Tshepo B Leeme; Nametso Tlhako; Katlego Tsholo; Tony Chebani; Anya Stephenson; Jemima Hutton; Hannah K Mitchell; Raju Kk Patel; William J Hurt; Tlhagiso Pilatwe; Tiny Masupe; Mooketsi Molefi; Brandon L Guthrie; Carey Farquhar; Madisa Mine; Joseph N Jarvis Journal: Lancet Infect Dis Date: 2019-07 Impact factor: 71.421
Authors: Elisa Ramos-Sevillano; Ana Urzainqui; Belén de Andrés; Rafael González-Tajuelo; Mirian Domenech; Fernando González-Camacho; Francisco Sánchez-Madrid; Jeremy S Brown; Ernesto García; Jose Yuste Journal: PLoS Pathog Date: 2016-03-14 Impact factor: 6.823
Authors: David M Lowe; Julie Demaret; Nonzwakazi Bangani; Justine K Nakiwala; Rene Goliath; Katalin A Wilkinson; Robert J Wilkinson; Adrian R Martineau Journal: Front Immunol Date: 2018-04-27 Impact factor: 7.561
Authors: Neil French; Robert S Heyderman; Todd D Swarthout; Claudio Fronterre; José Lourenço; Uri Obolski; Andrea Gori; Naor Bar-Zeev; Dean Everett; Arox W Kamng'ona; Thandie S Mwalukomo; Andrew A Mataya; Charles Mwansambo; Marjory Banda; Sunetra Gupta; Peter Diggle Journal: Nat Commun Date: 2020-05-06 Impact factor: 14.919
Authors: Alan Basset; Emma Wall; Daniela M Ferreira; Richard Malley; Elena Mitsi; Chloe Deshusses; Raecliffe Daly; Sherin Pojar; Jesús Reiné; Jose Afonso Guerra-Assuncao; Brigitte Denis; Simon P Jochems; Robert Heyderman; Jeremy Brown; Ying-Jie Lu Journal: Infect Immun Date: 2022-06-08 Impact factor: 3.609